Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Progression-Free Survival Is Adequate Primary Endpoint For Melanoma Trials

Executive Summary

Progression-free survival is an appropriate primary endpoint to support the approval of metastatic melanoma therapies, FDA's Oncologic Drugs Advisory Committee agreed
Advertisement

Related Content

Aventis, Genta To Meet With FDA After Genasense NDA Withdrawal
Aventis, Genta To Meet With FDA After Genasense NDA Withdrawal
Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte
Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte
Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte
Genasense Progression-Free Survival Data Do Not Show “Real Effect,” Cmte.
Genasense Progression-Free Survival Data Do Not Show “Real Effect,” Cmte.
Genentech Avastin Clears FDA; Colorectal Cancer Drug Costs $4,400 A Month
Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says
Advertisement
UsernamePublicRestriction

Register

PS043989

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel